Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | SAA treatment and QoL

Anita Hill • 13 Jun 2019
EHA 2019
Anemias Aplastic Anemia Immune Thrombocytopenia Non-Malignant

Anita Hill, MBChB (Hons), MRCP, FRCPath, PhD, Leeds Teaching Hospital NHS Trust, Leeds, UK, discusses optimizing treatment outcomes in severe aplastic anemia and immune thrombocytopenic purpura with thrombopoietin-receptor agonists (TPO-RAs), focussing on patient quality of life (QoL). Dr Hill goes on to discuss the use of patient-oriented surveys to asses QoL. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Anita Hill

1:25
Erythropoietin in AHA patients
Anita Hill • 13 Jun 2019
1:29
Treating Patients with PNH and AA
Anita Hill • 13 Jun 2019
2:05
Anita Hill: highlights from EHA 2019
Anita Hill • 13 Jun 2019
1:40
PNH treatment: ravulizumab vs. eculizumab
Anita Hill • 13 Jun 2019

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:45
A 2-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia
Antonio Risitano • 16 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals